Power Ultrasound and the Production of Mesoscopic Particles and Aqueous Dispersions - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Power Ultrasound and the Production of Mesoscopic Particles and Aqueous Dispersions
The authors discuss advanced sonocrystallization particle-engineering techniques for manufacturing mesoscopic particles.

Pharmaceutical Technology

The power of ultrasound

Sonocrystallization, or ultrasound-assisted crystallization, relies on the power-ultrasound (20–100 kHz) and extended-sonochemistry (100 kHz–2 MHz) bands of the acoustic-frequency range. By comparison, human hearing responds to frequencies between 20 Hz and 19 kHz.

Ultrasound involves mechanical vibrations that transfer energy by molecular motion. One consequence of ultrasound vibration is cavitation, the transient high-energy microbubbles formed when power ultrasound is applied to a liquid medium. The energy release associated with this phenomenon, once dissipated, can lead to permanent changes in the molecular structure of entities in close proximity.

Conversely, ultrasound can be used in various medical applications, diagnostic pulse-echo techniques, attenuation measurements, and particle separation, without any change to the medium or species suspended or dissolved in the liquid medium.

The acoustic bubble

The advantages that sonocrystallization offers over conventional crystallization largely result from cavitation. The microbubbles caused by cavitation are short-lived microreactors where responses and reactions such as chemical reaction and crystal nucleation take place in a uniquely favorable environment as large amounts of energy are transferred to reagent molecules in an extremely short time (6, 7).

Most ultrasound work has used either intense-probe or ultrasonic-bath-based equipment. Although cavitation is the essential element for successful sonocrystallization, including ultrasonic wet milling, it can be harmful to an ultrasound-radiating surface. Cavitation usually damages the ultrasonic device and creates problems with ultrasonic probes, where cavitation occurs close to the radiating surface. These engineering limitations can be overcome, however.

Small particles and sonocrystallization

Sonocrystallization can be applied at any stage of pharmaceutical manufacturing and lends itself to polymorphic systems (7, 8). The technique uses transient acoustic cavitation to assist in the nucleation of metastable solutions. By controlling nucleation, one controls and improves crystal-size distribution, morphology, impurities, polymorphism, and solid–liquid separation. Ultrasound can also induce secondary nucleation by mechanically disrupting crystals or loosely bound agglomerates.

Companies such as Prosonix, GlaxoSmithKline (Brentford, UK), AstraZeneca (London), and Syngenta (Basel) have patented crystallization methods based on ultrasound-assisted precipitation, principally for the preparation of nano- and microcrystalline particles (9–13). The cavitation-induced effects can be so strong that nanosuspensions can be prepared when the antisolvent is water.

Molecule-to-particle techniques using power ultrasound such as antisolvent precipitation take advantage of the excellent dispersive and crystal-nucleation properties of transient cavitation. Several companies that manufacture microparticles and nanosuspensions are adopting these techniques. Precipitation conditions must be chosen to maximize crystal nucleation at the expense of growth, which will necessitate having the appropriate prevailing supersaturation.

Rabinow gives a useful overview of the preparation, delivery, and performance of nanosuspenions, but in simple terms, a solution of the API must be added to the antisolvent (water) at an optimal rate to generate micrometer- and, where necessary, submicrometer-sized particles (3). One problem with this strategy is that supersaturation can force a phase separation and lead to oiling or rapid precipitation of amorphous forms and metastable polymorphs, because of slow nucleation kinetics. Yet more stable solid forms can eventually form, as indicated by Ostwald's law of stages. How does power ultrasound help?

Acoustic cavitation can have remarkable benefits for the system of interest, whether it is the manufacture of microparticles or nanosuspensions. Cavitation not only improves mixing and increases the diffusion of molecules toward a precrystal cluster or nucleus, it facilitates the formation of a crystalline phase (14). This latter effect is attributed to dramatic temperature and pressure changes, shockwaves, and rapid local cooling rates (15).

The continuous mixing of a solution of API in a suitable miscible solvent with an antisolvent, whether water or an organic solvent, in a flow cell fitted with an ultrasonic probe shows the potential of the sonoprecipitation and sonocrytallization of microcrystalline pharmaceutical products (11). During the course of the process, the solvent–antisolvent ratio always remains constant, and flow rates must be balanced. Nevertheless, this continuous technique has potential advantages.

Water-insoluble drug substances can be dissolved in a water-miscible organic solvent that can then be added to water in the presence of an ultrasonic field. The ultrasound can be applied using an immersed ultrasonic probe to generate a dispersion. The form of the dispersion depends upon ultrasonic energy and the presence or absence of stabilizers (12). Even though acoustic cavitation occurs during the initial mixing, amorphous particles are produced. Amorphous particles are considered essential for avoiding crystal growth if crystalline phases are present. Applying continuous ultrasound after mixing leads to the formation of crystalline submicrometer-sized particles through a solution-mediated amorphous-to-crystalline transition.

If it is important to avoid organic solvents and the organic compound of interest has a suitably low melting point, sonocrystallization can aid antisolvent crystallization in several ways. Sonocrystallization typically helps through a process that disperses the melted liquid into the antisolvent water, solidifies the melted droplets, and subsequently or concurrently crystallizes the compound (13). The ability to apply any particle-engineering methodology or technology on an industrial scale is paramount.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here